



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2018





HIV/AIDS Drug Treatment Program

Monthly Report

© 2018 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2018

N = 7285



Health Authority	Male	Female	All
FRASER	1387	402	1789
INTERIOR	376	100	476
NORTHERN	136	78	214
VANCOUVER COASTAL	3420	462	3882
VANCOUVER ISLAND	730	150	880
	6049	1192	7241
		Unknown/not stated:	44
		Total:	7285

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2013 - March 2018)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2013 - March 2018)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2013 - March 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(March 2013 - March 2018)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2013 - March 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count (March 2013 - March 2018)






1.8 Active and Inactive Participants (March 2013 - March 2018)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2013 - March 2018)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (March 2013 - March 2018)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2013 - March 2018)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2013 - March 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2013 - March 2018)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2013 - March 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2013 - March 2018)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2013 - March 2018)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2013 - March 2018)






1.18 Baseline CD4 for Antiretroviral First Starts (March 2013 - March 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(March 2013 - March 2018)**






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2013 - March 2018)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2013 - March 2018)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2018
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	4	0	4	4	870	4	<40	4
1988	27	7	0	7	7	450	7	<40	3
1989	25	55	2	57	48	500	55	<40	3
1990	24	61	1	62	60	520	62	<40	3
1991	24	38	3	41	31	540	39	<40	3
1992	24	66	5	71	55	570	67	<40	3
1993	23	142	15	157	144	580	155	<40	3
1994	21	87	14	101	82	585	98	<40	3
1995	21	129	21	150	128	590	143	<40	3
1996	19	361	57	418	363	600	405	<40	3
1997	17	295	36	331	286	650	303	<40	3
1998	17	201	43	244	215	560	240	<40	3
1999	16	171	41	212	181	580	202	<40	3
2000	17	126	36	162	136	570	151	<40	3
2001	16	129	32	161	134	555	154	<40	3
2002	15	133	30	163	133	580	152	<40	3
2003	14	162	31	193	160	610	177	<40	3
2004	13	170	41	211	176	600	203	<40	3
2005	13	189	49	238	202	620	232	<40	3
2006	11	197	48	245	206	585	228	<40	3
2007	11	266	48	314	264	600	292	<40	3
2008	10	304	68	372	306	630	346	<40	3
2009	9	335	71	406	345	630	385	<40	3
2010	8	292	70	362	307	630	346	<40	3
2011	7	343	75	418	352	670	390	<40	3
2012	6	282	66	348	302	700	337	<40	3
2013	5	276	68	344	279	650	324	<40	3
2014	4	298	55	353	286	720	327	<40	3
2015	3	300	48	348	290	680	333	<40	3
2016	2	306	64	370	318	665	356	<40	3
2017	1	260	39	299	270	610	293	<40	3
2018	0	79	13	92	89	540	90	191	3
Total:		6064	1190	7254					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2074	590
FEB-2017	7134	755	1914	<40	1739	590
MAR-2017	7186	745	2203	<40	2017	600
APR-2017	7178	746	1966	<40	1767	590
MAY-2017	7224	744	2276	<40	2056	590
JUN-2017	7245	752	2120	<40	1952	593
JUL-2017	7241	753	1965	<40	1784	580
AUG-2017	7266	757	2106	<40	1881	590
SEP-2017	7222	762	2041	<40	1836	610
OCT-2017	7246	770	2189	<40	1930	610
NOV-2017	7245	766	2074	<40	1855	610
DEC-2017	7229	776	1740	<40	1512	610
JAN-2018	7293	756	2385	<40	2048	613
FEB-2018	7258	765	1902	<40	1648	611
MAR-2018	7285	774	2049	<40	1719	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1403	3151	88	140	79	420
FEB-2017	1456	2851	80	1874	70	400
MAR-2017	1409	3132	99	635	89	380
APR-2017	1425	3087	94	545	84	420
MAY-2017	1397	3271	85	180	75	420
JUN-2017	1387	3356	76	197	68	485
JUL-2017	1408	3240	68	376	61	520
AUG-2017	1401	3308	78	160	68	495
SEP-2017	1458	3054	74	323	66	415
OCT-2017	1430	3223	89	218	78	455
NOV-2017	1447	3144	78	163	68	360
DEC-2017	1480	3039	60	53	50	382
JAN-2018	1435	3270	78	872	69	350
FEB-2018	1479	3096	81	264	64	455
MAR-2018	1461	3168	76	54	62	485

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1403	21	21	141	142	-6	12877
FEB-2017	7102	1456	10	24	136	182	-38	12911
MAR-2017	7147	1409	17	19	189	139	45	12937
APR-2017	7139	1425	12	20	143	151	-8	12969
MAY-2017	7194	1397	7	22	170	126	55	13003
JUN-2017	7210	1387	10	24	151	138	16	13033
JUL-2017	7202	1408	7	14	134	143	-8	13052
AUG-2017	7229	1401	10	25	156	137	27	13082
SEP-2017	7185	1458	12	16	137	180	-44	13111
OCT-2017	7214	1430	7	6	184	149	29	13124
NOV-2017	7210	1447	16	19	142	146	-4	13159
DEC-2017	7201	1480	4	18	155	175	-9	13190
JAN-2018	7255	1435	13	12	191	129	54	13219
FEB-2018	7227	1479	10	27	123	167	-28	13256
MAR-2018	7254	1461	17	23	156	133	27	13285

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	58	7186	0.83%	92.25%	6.11%	0.81%	100.00%
APR-2017	58	6633	428	59	7178	0.81%	92.41%	5.96%	0.82%	100.00%
MAY-2017	62	6665	438	59	7224	0.86%	92.26%	6.06%	0.82%	100.00%
JUN-2017	57	6691	438	59	7245	0.79%	92.35%	6.05%	0.81%	100.00%
JUL-2017	61	6685	433	62	7241	0.84%	92.32%	5.98%	0.86%	100.00%
AUG-2017	61	6696	448	61	7266	0.84%	92.16%	6.17%	0.84%	100.00%
SEP-2017	57	6677	431	57	7222	0.79%	92.45%	5.97%	0.79%	100.00%
OCT-2017	58	6693	438	57	7246	0.80%	92.37%	6.04%	0.79%	100.00%
NOV-2017	59	6685	445	56	7245	0.81%	92.27%	6.14%	0.77%	100.00%
DEC-2017	58	6668	447	56	7229	0.80%	92.24%	6.18%	0.77%	100.00%
JAN-2018	58	6729	451	55	7293	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	61	6688	451	58	7258	0.84%	92.15%	6.21%	0.80%	100.00%
MAR-2018	62	6714	453	56	7285	0.85%	92.16%	6.22%	0.77%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3242 46%	5 38%	2984 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3716 53%
NOV-2017	9 26%	3283 47%	8 23%	3027 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3663 52%
DEC-2017	10 32%	3287 47%	10 32%	3033 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3613 52%
JAN-2018	10 36%	3320 47%	9 32%	3076 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3634 51%
FEB-2018	13 35%	3320 47%	12 32%	3078 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3588 51%
MAR-2018	10 34%	3344 47%	10 34%	3108 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	312 4%	19 66%	3568 50%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3732	53%
NOV-2017	26	74%	3695	53%
DEC-2017	21	68%	3666	52%
JAN-2018	18	64%	3710	52%
FEB-2018	24	65%	3682	52%
MAR-2018	19	66%	3675	52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1365 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1325 45%	10 83%	1392 47%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1317 45%	7 70%	1419 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1259 44%	15 100%	1422 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1248 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	264 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	748 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	251 12%	0 0%	736 36%	2 67%	311 15%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1757 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1791 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	10 71%	1833 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	8 89%	1880 59%	1 11%	608 19%	0 0%	48 1%	0 0%	708 22%	0 0%	0 0%
NOV-2017	14 67%	1941 60%	5 24%	612 19%	0 0%	49 2%	2 10%	701 21%	0 0%	0 0%
DEC-2017	11 69%	1959 60%	5 31%	604 18%	0 0%	48 1%	0 0%	689 21%	0 0%	0 0%
JAN-2018	9 47%	2007 60%	8 42%	631 19%	0 0%	46 1%	2 11%	689 21%	0 0%	0 0%
FEB-2018	16 70%	2028 60%	6 26%	643 19%	0 0%	45 1%	1 4%	676 20%	0 0%	0 0%
MAR-2018	14 88%	2062 61%	2 13%	649 19%	0 0%	43 1%	0 0%	676 20%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2051	28.31	1674	23.10	2477	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2005	27.67	1668	23.02	2522	34.81	119	1.64	56	0.77	875	12.08
DEC-2017	1998	27.64	1660	22.96	2533	35.04	115	1.59	56	0.77	867	11.99
JAN-2018	2008	27.53	1645	22.56	2596	35.60	117	1.60	55	0.75	872	11.96
FEB-2018	1968	27.11	1630	22.46	2618	36.07	116	1.60	58	0.80	868	11.96
MAR-2018	1980	27.18	1616	22.18	2652	36.40	113	1.55	56	0.77	868	11.91

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	1	2	450
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	23	4	1	5	4	8	355

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11566	3386
FEB-2017	11591	3393
MAR-2017	11642	3442
APR-2017	11668	3457
MAY-2017	11709	3482
JUN-2017	11738	3498
JUL-2017	11771	3529
AUG-2017	11806	3555
SEP-2017	11833	3580
OCT-2017	11890	3634
NOV-2017	11902	3633
DEC-2017	11930	3639
JAN-2018	11989	3682
FEB-2018	12018	3695
MAR-2018	12045	3722

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2018

N = 7285

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2018

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	35	48	23
KOOTENAY BOUNDARY	0-19	*	*	0
	20-34	*	*	0
	35-49	*	*	10
	50+	*	*	42
Total HSDA:	72	95	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	349	469	265	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	40
	50+	*	*	77
Total HSDA:	176	236	136	
Total HA:		632	848	476

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		632	848	476

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	495	673	376
Female	137	175	100

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	476	54	590	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	*
	5 years or more	6	*
	<5 years	11	*
	Total HSDA:	35	23
KOOTENAY BOUNDARY	10 years or more	40	28
	5 years or more	20	16
	<5 years	12	8
	Total HSDA:	72	52
OKANAGAN	10 years or more	202	143
	5 years or more	73	60
	<5 years	74	62
	Total HSDA:	349	265
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	92	63
	5 years or more	36	34
	<5 years	48	39
	Total HSDA:	176	136
Total HA:		632	476

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	352	245
	5 years or more	135	114
	<5 years	145	117
Total HA:		632	476

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	38	55	13	22
KOOTENAY BOUNDARY	66	116	24	43
OKANAGAN	205	766	65	267
THOMPSON/CARIBOO/SHUSWAP	126	464	37	121
Total:	435	1401	139	453

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	83

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	28	29	21
	35-49	106	117	76
	50+	203	272	158
	Total HSDA:	343	424	260
FRASER NORTH	0-19	12	12	*
	20-34	108	109	*
	35-49	343	380	*
	50+	515	816	*
	Total HSDA:	978	1317	757
FRASER SOUTH	0-19	7	7	5
	20-34	102	104	74
	35-49	356	407	289
	50+	475	707	404
	Total HSDA:	940	1225	772
Total HA:		2261	2966	1789

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	25	25	12
	20-34	238	242	178
	35-49	805	904	624
	50+	1193	1795	975
Total HA:		2261	2966	1789

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1723	2287	1387
Female	538	679	402

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1789	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	180	129
	5 years or more	94	75
	<5 years	69	56
	Total HSDA:	343	260
FRASER NORTH	10 years or more	494	353
	5 years or more	250	195
	<5 years	234	209
	Total HSDA:	978	757
FRASER SOUTH	10 years or more	465	373
	5 years or more	238	188
	<5 years	237	211
	Total HSDA:	940	772
Total HA:		2261	1789

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1139	855
	5 years or more	582	458
	<5 years	540	476
Total HA:		2261	1789

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	133	455	37	74
FRASER NORTH	241	1520	55	248
FRASER SOUTH	209	1272	44	355
Total:	583	3247	136	677

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	192
FRASER NORTH	650
FRASER SOUTH	519
Total:	1361

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	23
	35-49	*	*	71
	50+	*	*	191
	Total HSDA:		323	466
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		162	209
VANCOUVER	0-19	40	43	5
	20-34	442	453	329
	35-49	1480	1681	1091
	50+	2661	4488	2047
	Total HSDA:	4623	6665	3472
Total HA:		5108	7340	3882

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	44	47	6
	20-34	490	502	366
	35-49	1607	1824	1194
	50+	2967	4967	2316
Total HA:		5108	7340	3882

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4484	6440	3420
Female	622	898	462

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3882	52	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	169	143
	5 years or more	76	67
	<5 years	78	75
	Total HSDA:	323	285
RICHMOND	10 years or more	83	61
	5 years or more	41	33
	<5 years	38	31
	Total HSDA:	162	125
VANCOUVER	10 years or more	2527	1826
	5 years or more	1206	913
	<5 years	890	733
	Never on ART	0	0
	Total HSDA:	4623	3472
Total HA:	5108	3882	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2779	2030
5 years or more	1323	1013
<5 years	1006	839
Never on ART	0	0
Total HA:	5108	3882

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	159	438	57	145
RICHMOND	42	276	14	93
VANCOUVER	567	10456	211	5359
Total:	768	11170	282	5597

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	168

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		311	432
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	159
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		703	986
Total HA:		1135	1577	880

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	100	106	*
	35-49	315	361	*
	50+	711	1101	*
Total HA:		1135	1577	880

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	929	1292	730
Female	206	285	150

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	880	53	510	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	149	121
	5 years or more	75	63
	<5 years	87	70
	Total HSDA:	311	254
NORTH VANCOUVER ISLAND	10 years or more	65	56
	5 years or more	30	21
	<5 years	26	17
	Total HSDA:	121	94
SOUTH VANCOUVER ISLAND	10 years or more	382	270
	5 years or more	158	129
	<5 years	163	133
	Total HSDA:	703	532
Total HA:		1135	880

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	596	447
	5 years or more	263	213
	<5 years	276	220
Total HA:		1135	880

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	185	822	78	202
NORTH VANCOUVER ISLAND	124	253	40	72
SOUTH VANCOUVER ISLAND	204	1691	46	550
Total:	513	2766	164	824

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	34
SOUTH VANCOUVER ISLAND	104
Total:	189

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	15
	50+	*	*	29
	Total HSDA:		70	106
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	26	*
	35-49	77	94	*
	50+	86	138	*
	Total HSDA:		191	264
Total HA:		301	418	214

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	35	40	*
	35-49	114	150	*
	50+	143	219	*
Total HA:		301	418	214

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	185	261	136
Female	116	157	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	214	50	520	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	19	11
	5 years or more	12	7
	<5 years	9	6
	Total HSDA:	40	24
NORTH WEST	10 years or more	23	11
	5 years or more	32	28
	<5 years	15	11
	Total HSDA:	70	50
NORTHERN INTERIOR	10 years or more	63	39
	5 years or more	71	59
	<5 years	57	42
	Total HSDA:	191	140
Total HA:		301	214

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	105	61
	5 years or more	115	94
	<5 years	81	59
Total HA:		301	214

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	37	61	9	10
NORTH WEST	68	152	17	29
NORTHERN INTERIOR	103	427	17	179
Total:	208	640	43	218

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	16
NORTHERN INTERIOR	23
Total:	46

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	33	*
	THOMPSON/CARIBOO/SHUSWAP	*	39	*
	Total HA:	50	89	33
FRASER	FRASER EAST	34	43	25
	FRASER NORTH	50	83	41
	FRASER SOUTH	69	100	54
	Total HA:	153	226	120
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	48	26
	RICHMOND	11	16	10
	VANCOUVER	507	839	426
	Total HA:	544	903	462
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	77	42
	NORTH VANCOUVER ISLAND	17	26	12
	SOUTH VANCOUVER ISLAND	34	74	28
	Total HA:	102	177	82
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	33	60	26
	NORTHERN INTERIOR	68	102	58
	Total HA:	110	173	91
Total:		959	1568	788

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	592	1000	484
Female	367	568	304

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	788	50	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

